Equities

Katakura Industries Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Katakura Industries Co Ltd

Actions
IndustrialsGeneral Industrials
  • Price (JPY)3,025.00
  • Today's Change-120.00 / -3.82%
  • Shares traded56.10k
  • 1 Year change+51.25%
  • Beta0.1766
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Katakura Industries Co.,Ltd. is a Japan-based company mainly engaged in the real estate operation and leasing, as well as the manufacture and sale of mechanical maintenance products and auto parts. The Company operates through four business segments. The Textile segment is engaged in the manufacture and sale of underwear, socks, silk products, casual innerwear, adjusted underwear and functional fibers, as well as the brand licensing business. The Pharmaceutical segment manufactures and sells ethical drugs. The Machinery-Related segment manufactures and sells fire trucks, automobile parts, agricultural machinery and imports and sells petroleum products. The Real Estate segment operates shopping centers and rents real estate. The Company is also involved in the home improvement, building management services, sales of flower visiting insects, low potassium lettuce, production and sales of Hanabiratake and day services.

  • Revenue in JPY (TTM)40.98bn
  • Net income in JPY5.84bn
  • Incorporated1920
  • Employees941.00
  • Location
    Katakura Industries Co LtdNichirei Akashicho Bldg.6-4, Akashi-choCHUO-KU 104-8312JapanJPN
  • Phone+81 368321873
  • Fax+81 368320256
  • Websitehttps://www.katakura.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fuji Pharma Co Ltd54.57bn2.33bn56.00bn1.76k23.571.158.901.0395.4695.462,233.291,959.480.57651.492.8331,007,950.002.464.513.936.7640.8240.574.278.510.87617.580.388525.9812.018.87-51.197.558.077.94
ASKA Pharmaceutical Holdings Co Ltd68.70bn4.91bn69.12bn1.63k13.900.99278.921.01172.92172.922,421.072,420.680.67291.373.6242,094,980.004.935.506.647.0748.3347.567.327.981.2375.350.155116.602.064.07-32.3951.049.4931.48
Oncolys Biopharma Inc28.55m-2.06bn71.47bn35.00--17.86--2,503.73-80.66-80.661.11136.640.00740.000.1004---53.08-53.26-58.54-60.190.00---7,209.58-484.939.54-424.600.0741---9.04-38.10-22.16--2.22--
Cuorips Inc355.69m-764.60m78.11bn56.00--15.56--219.59-93.30-93.3043.60607.390.06563.33238.006,351,607.00-14.20---14.62--76.69---216.57--36.81--0.00--658.40---1.92------
Nxera Pharma Co Ltd28.70bn-6.14bn78.55bn374.00--1.20--2.74-68.13-68.13318.44725.520.19361.474.5776,737,970.00-4.14-1.71-4.63-1.8571.1784.07-21.41-10.932.55-11.730.4902--125.8724.2832.74--40.57--
JCR Pharmaceuticals Co Ltd37.55bn-2.44bn85.46bn987.00--1.74183.792.28-19.98-19.98307.86379.760.34320.45342.5038,039,510.00-2.215.86-3.779.3370.4573.83-6.4513.600.668--0.529545.13-22.865.94-186.42--15.3720.11
Kyorin Pharmaceutical Co Ltd133.26bn10.77bn99.87bn2.00k8.890.68926.490.7495187.40187.402,319.592,417.370.69271.082.9366,695,200.005.603.347.034.1645.3245.898.085.112.05--0.174657.348.833.4170.738.1214.36-7.06
Katakura Industries Co Ltd40.98bn5.84bn106.53bn941.0016.591.0612.112.60182.30182.301,278.512,853.060.29262.156.4243,545,160.004.272.605.203.5736.1637.9814.599.442.63--0.080723.42-1.37-2.1915.7315.27-7.2233.03
Zeria Pharmaceutical Co Ltd86.61bn7.26bn113.33bn1.75k13.451.027.791.31164.79164.791,964.972,178.210.53661.273.2149,607,640.004.494.676.997.4772.7672.178.379.020.973911.410.298428.7515.307.6428.5227.7116.516.69
Mochida Pharmaceutical Co Ltd111.92bn6.42bn135.73bn1.51k20.590.962114.461.21181.16181.163,156.953,876.770.64271.673.0274,214,190.003.694.504.475.4448.4352.495.746.872.85--0.067843.012.210.651625.034.341.980.00
Data as of Feb 13 2026. Currency figures normalised to Katakura Industries Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

14.07%Per cent of shares held by top holders
HolderShares% Held
Zennor Asset Management LLPas of 05 Feb 20261.59m4.51%
The Vanguard Group, Inc.as of 07 Jan 2026704.34k2.00%
Nomura Asset Management Co., Ltd.as of 08 Jan 2026650.10k1.85%
Morant Wright Management Ltd.as of 31 Dec 2025450.00k1.28%
Dimensional Fund Advisors LPas of 30 Nov 2025419.95k1.19%
Amova Asset Management Co., Ltd.as of 09 Jan 2026398.70k1.13%
Daiwa Asset Management Co. Ltd.as of 30 Dec 2025292.30k0.83%
Gutmann KAGas of 29 Aug 2025175.50k0.50%
Norges Bank Investment Managementas of 30 Jun 2025143.00k0.41%
Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 2026135.20k0.38%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.